Pelthos Therapeutics (PTHS) Change in Accured Expenses (2023 - 2026)

Pelthos Therapeutics' Change in Accured Expenses history runs 3 years deep, the most recent figure standing at $3.5 million for Q4 2025.

• In Q4 2025, Change in Accured Expenses changed N/A year-over-year to $3.5 million; the TTM figure through Dec 2025 stood at $6.2 million (up 2277.74% YoY), while the FY2025 annual figure was $6.2 million, up 2277.74% from the prior year.
• Change in Accured Expenses for Q4 2025 stood at $3.5 million, up from $2.7 million in the prior quarter.
• The five-year high for Change in Accured Expenses was $3.5 million in Q4 2025, with the low at -$1.6 million in Q2 2024.
• The 3-year median for Change in Accured Expenses is $121995.0 (2023), against an average of $573097.5.
• The sharpest annual moves came in 2024 and 2025: Change in Accured Expenses plunged 468.78% in 2024, then jumped 676.4% in 2025.
• Pelthos Therapeutics' Change in Accured Expenses stood at $83911.0 in 2023, then soared by 1327.84% to $1.2 million in 2024, then jumped by 189.96% to $3.5 million in 2025.
• Business Quant data shows PTHS's Change in Accured Expenses at $3.5 million in Q4 2025, $2.7 million in Q3 2025, and -$682842.0 in Q2 2025.